Pharmacy Times

JULY 24, 2024

The decision offers patients with difficulty swallowing their medication expanded options for treatment administration.

FDA 149

FDA 149

STAT

JULY 24, 2024

In 1988, I became one of the first U.S. physicians certified in the new specialty of geriatric medicine, which focuses on the health care of older adults. As an idealistic and optimistic 32-year-old geriatrician, I believed that this branch of medicine would undoubtedly emerge as a vibrant field of medicine, benefiting patients and society. I was also confident that when I reached older adulthood, the health care system would be ready to care for me.

143

143

Pharmacy Times

JULY 24, 2024

Studies show an increased prevalence of autism spectrum disorder in children of mothers; mouse models have shown links between maternal asthma and altered behavior and brain function.

138

138

STAT

JULY 24, 2024

Jiankui He, the Chinese scientist who s parked a global uproar in 2018 when he revealed he had created the first gene-edited children , is again out on his own after being dismissed from an academic post. In January 2019, provincial health authorities found that He’s human CRISPR experiments violated national regulations against gene-editing for reproductive purposes.

143

143

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

JULY 24, 2024

Emerging treatments, collaboration between health care providers, and new policy proposals have led to a positive outlook for the future of nonalcoholic steatohepatitis (NASH) and its treatment.

132

132

STAT

JULY 24, 2024

Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing the biotech closer to joining the highly competitive GLP-1 drug market.  The San Diego-based biotech previously said it was anticipating to start a Phase 2b trial of the therapy, VK2735, after getting positive results from a Phase 2 study.

141

141

STAT

JULY 24, 2024

A key piece of disability civil rights law could get a much-needed refresh. Sen. Bob Casey Jr. (D-Pa.) will introduce legislation Wednesday to strengthen and extend Section 508 of the Rehabilitation Act of 1973. The proposed update would boost online accessibility for people with disabilities on federal websites and significantly expand protections and working conditions for disabled federal employees.

139

139

Fierce Healthcare

JULY 24, 2024

The Centers for Medicare & Medicaid Services (CMS) has released new data on risk adjustment payments for 2023. | The Centers for Medicare & Medicaid Services has released new data on risk adjustment payments for 2023.

Insurance 124

Insurance 124

STAT

JULY 24, 2024

Pfizer said Wednesday that its gene therapy for hemophilia A successfully reduced patients’ bleeds for at least 15 months in a large phase 3 trial. The data may be enough to muster approval, but they are unlikely to quell doubts about whether the treatment can provide a cure — as had once been hoped — or a meaningful option for most patients in the U.S. and Europe with the rare blood disorder.

Hospitals 131

Hospitals 131

Drug Topics

JULY 24, 2024

PASO DOBLE is the largest head-to-head, phase 4 randomized clinical trial comparing DTG/3TC and BIC/FTC/TAF in patients with HIV.

123

123

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JULY 24, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning. Several of my colleagues have joined the newsletter today to bring you the latest biopharma updates. It’s a busy news day, especially for a summer Wednesday, so let’s get straight into it.

128

128

Pharmacy Times

JULY 24, 2024

In April 2017, the drug was approved to treat the slow loss of the ability to walk for symptomatic patients aged 3 and older who had Batten disease.

FDA 122

FDA 122

STAT

JULY 24, 2024

For many kids with cerebral palsy, walking is taxing. They might spend thousands of hours step-stepping in physical therapy to make walking easier. In recent years researchers have developed robots to aid this rehabilitation. A new JAMA Network Open study from a team in South Korea found that exoskeletons can improve a child’s gait, balance and motor function.

124

124

BioPharm

JULY 24, 2024

GSK’s submission is supported by Phase III trials showing significant progression-free survival benefit and positive overall survival trends using Blenrep combinations compared to standard care.

122

122

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

JULY 24, 2024

Stay updated on Matteo Levisetti, the chief medical officer at CUE Biopharma, post ASCO 2024. Learn about his latest research and contributions in the field of biopharma.

116

116

Fierce Pharma

JULY 24, 2024

From flubbing data to performing aseptic processing with torn and stained gowns, Brassica Pharma’s recent warning letter from the FDA reads like a textbook example of what not to do when the U.S. | From flubbing data to performing aseptic processing with torn and stained gowns, Brassica Pharma’s recent warning letter from the FDA reads like a textbook example of what not to do when the U.S. regulator comes knocking at your facility.

FDA 115

FDA 115

Drug Topics

JULY 24, 2024

Full efficacy and safety results for the phase 3 PURPOSE 1 trial were announced by Gilead at AIDS 2024.

112

112

Pharmacy Times

JULY 24, 2024

It is essential for clinicians to properly diagnose patients with suspected AVWS and provide them proper treatment, which could be intravenous immunoglobulin.

111

111

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Drug Topics

JULY 24, 2024

Data will be discussed with regulatory authorities “in the coming months.

112

112

pharmaphorum

JULY 24, 2024

Explore the latest developments in the life sciences industry with a focus on patient-centred research and development (R&D) at DIA 2024. Chart new horizons and stay updated on key trends shaping the future of healthcare.

111

111

Fierce Pharma

JULY 24, 2024

HOPEWELL, NEW JERSEY—A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in biologics. | A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in biologics.

110

110

pharmaphorum

JULY 24, 2024

The top three pharmacy benefit managers in the US felt the heat at a hearing of the House Oversight Committee, as lawmakers grilled executives over their business practices and accused them of monopolising the supply chain.

111

111

Med Ed 101

JULY 24, 2024

In this post, I will share some questions that I would investigate from this medication list. I have many questions surrounding renal concerns given the use of sevelamer. Sevelamer is a phosphate binder that is typically used to lower phosphate levels for patients with CKD. If this patient truly has CKD and significant impairment, many […] The post Med List Review – Renal Concerns appeared first on Med Ed 101.

105

105

pharmaphorum

JULY 24, 2024

Asarina Pharma has abandoned its partner search for Tourette's drug sepranolone and will go into liquidation.

110

110

Pharmaceutical Commerce

JULY 24, 2024

The latest news for pharma industry insiders.

105

105

pharmaphorum

JULY 24, 2024

MSD's phase 2b/3 data with clesrovimab for RSV prevention in infants sets up a challenge to Sanofi and AstraZeneca's fast-growing Beyfortus

105

105

STAT

JULY 24, 2024

Sage Therapeutics said Wednesday that an experimental pill failed to quell involuntary muscle shaking in patients with a neurological condition called essential tremor. The negative study result for the drug, called SAGE-324, is a significant setback for Sage’s neurology pipeline, and its effort to develop a successful medicine beyond Zurzuvae, an approved treatment for postpartum depression.

105

105

pharmaphorum

JULY 24, 2024

Biogen's $3bn alliance with Sage has had another setback after a drug for essential tremor failed a phase 2 study.

103

103

STAT

JULY 24, 2024

Cutting-edge FDA-approved therapies made from human cells are now being used to treat cancer, diabetes, and other diseases. Currently, most approved cell-based therapies use an individual’s own cells, but the next generation of these therapies will be made from donor-derived blood and tissue. That raises critical questions about how to recruit, retain, and fairly compensate donors while ensuring their safety throughout the donation process.

FDA 105

FDA 105

Pharmacy Times

JULY 24, 2024

Education about prevention measures and early signs and symptoms of the condition are crucial

100

100

Drug Topics

JULY 24, 2024

Check out these featured Drug Topics interviews from July 2024.

98

98

Pharmaceutical Technology

JULY 24, 2024

The crowd and panel gave Gilead a standing ovation after the full data from the Phase III PURPOSE trial was announced at AIDS 2024.

98

98

Drug Topics

JULY 24, 2024

In part 3 of his conversation with Drug Topics on Over the Counter, Mayank Amin, PharmD, RPh, MBA, continues his inspiring story of reopening Skippack Pharmacy and details the beginnings of The Superman Pharmacist.

Community Pharmacies 98

Community Pharmacies 98